Liting Chen
Impact in
- Oncology top 5%
- CAR-T cell therapy research
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
- Oncology 47
- CAR-T cell therapy research 37
- Immunology 21
- Immunotherapy and Immune Responses 8
- Immune Cell Function and Interaction 6
- Co-authors
- Wu Keqiang (2 shared papers)Ming Luo (1 shared paper)Yuyuan Wang (1 shared paper)Jianfeng Zhou (30 shared papers)Xinlin Yang (1 shared paper)Xiaoying Yang (1 shared paper)Bo Sheng Huang (1 shared paper)Feng Bai (1 shared paper)
- Journals
- Journal for ImmunoTherapy of Cancer (4 papers)Nature Communications (4 papers)Frontiers in Immunology (4 papers)Blood (4 papers)International Journal of Molecular Sciences (3 papers)
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Liting Chen
175 papers receiving 4.0k citations
Liting Chen's Hit Papers
Peers
Comparison fields: 5 of 157
- Oncology 998
- Infectious Diseases 399
- Hematology 221
- Molecular Biology 1.3k
- Plant Science 654
Countries citing papers authored by Liting Chen
This map shows the geographic impact of Liting Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liting Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liting Chen more than expected).
Fields of papers citing papers by Liting Chen
This network shows the impact of papers produced by Liting Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liting Chen. The network helps show where Liting Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Liting Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 193 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial Hit paper breakdown → | 2020 | 359 |
| 2 | 2010 | 291 | |
| 3 | 2019 | 220 | |
| 4 | 2020 | 199 | |
| 5 | 2010 | 183 | |
| 6 | 2021 | 163 | |
| 7 | 2021 | 137 | |
| 8 | 2009 | 120 | |
| 9 | 2020 | 67 | |
| 10 | 2019 | 63 | |
| 11 | 2021 | 61 | |
| 12 | 2013 | 55 | |
| 13 | 2010 | 54 | |
| 14 | 2019 | 51 | |
| 15 | 2021 | 51 | |
| 16 | 2013 | 47 | |
| 17 | 2016 | 46 | |
| 18 | 2018 | 44 | |
| 19 | 2022 | 44 | |
| 20 | 2020 | 41 |
About Liting Chen
Liting Chen is a scholar working on Oncology, Immunology, Molecular Biology, Genetics and Hematology, having authored 193 papers that have together received 4.0k indexed citations. Recurring topics across this work include CAR-T cell therapy research (37 papers), Virus-based gene therapy research (15 papers), Lymphoma Diagnosis and Treatment (9 papers), Immunotherapy and Immune Responses (8 papers), Viral Infectious Diseases and Gene Expression in Insects (7 papers), Liver Disease Diagnosis and Treatment (6 papers), Mitochondrial Function and Pathology (6 papers) and Immune Cell Function and Interaction (6 papers). The work is most often cited by research in Oncology (998 citations), Infectious Diseases (399 citations), Hematology (221 citations), Molecular Biology (1.3k citations) and Plant Science (654 citations). Liting Chen has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Wu Keqiang, Ming Luo, Yuyuan Wang, Jianfeng Zhou, Xinlin Yang, Xiaoying Yang, Bo Sheng Huang, Feng Bai, Yang Cao and Xiaolu Long. Their work appears in journals such as Journal for ImmunoTherapy of Cancer, Nature Communications, Frontiers in Immunology, Blood and International Journal of Molecular Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.